GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Valuation Rank

Ionis Pharmaceuticals (STU:ISI) Valuation Rank


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ionis Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (STU:ISI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Valuation Rank
Comparable Companies
HALO BBIO CYTK APLS MDGL EXEL CRSP KRYS RVMD IBRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IONS:USA IONS:Mexico ISI:Germany
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Website
https://www.ionispharma.com
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).